Data of the China GRSP are owned by China\'s National Center for STD Control and CAMS Institute of Dermatology but the de-identified data in a spreadsheet are provided as a supplemental document.

Introduction {#sec007}
============

Gonorrhea, caused by *Neisseria gonorrhoeae* (*N*. *gonorrhoeae*), remains one of the most common sexually transmitted diseases (STDs) worldwide. In 2012, the World Health Organization (WHO) estimated 27 million prevalent and 78 million incident cases of gonorrhea among people 15--49 years old. Of these estimated numbers, 42.5% and 45%, respectively, occurred in the Western Pacific Region. China is the most populous country in this region and contributes substantially to the number of people with gonorrhea \[[@pmed.1002499.ref001]\]. China reports approximately 115,000 new cases of gonorrhea annually. The incidence of gonorrhea has increased in recent years, and the infection has become one of the most common notifiable infectious diseases in the country \[[@pmed.1002499.ref002]\]. Gonorrhea causes urethritis, cervicitis, pharyngitis, and anal infection. If left untreated, it can result in complications such as pelvic inflammatory disease in women \[[@pmed.1002499.ref003]\] and infertility in both men and women \[[@pmed.1002499.ref004]\]. Moreover, it increases the risk for HIV acquisition and transmission \[[@pmed.1002499.ref005]\]. Control of gonorrhea in many countries largely relies on detection of cases followed by therapy to cure the infection and eliminate transmission to others. However, successful treatment has been hampered by emerging resistance to each of the antibiotics recommended as first-line therapies \[[@pmed.1002499.ref006]\]. Latest in this trend are resistance and treatment failures for extended-spectrum cephalosporins, including ceftriaxone and cefixime \[[@pmed.1002499.ref007],[@pmed.1002499.ref008]\]. Monotherapy with ceftriaxone (250 mg intramuscularly in a single dose) for uncomplicated gonococcal infections is still the recommended regimen in the current guidelines in China. To halt the development and spread of resistance, dual therapy consisting of ceftriaxone and azithromycin has been recommended as the first-line therapy in international and national guidelines \[[@pmed.1002499.ref009]--[@pmed.1002499.ref011]\]. However, the first treatment failure with dual therapy was reported in 2016 in the United Kingdom \[[@pmed.1002499.ref012]\]. To provide evidence for updating China's national treatment recommendations for gonorrhea, we analyzed data on the susceptibility to azithromycin and ceftriaxone of *N*. *gonorrhoeae* isolates collected in the China Gonococcal Resistance Surveillance Programme (China-GRSP).

Methods {#sec008}
=======

Ethical clearance {#sec009}
-----------------

The study was approved by the Medical Ethics Committee at the Institute of Dermatology, the Chinese Academy of Medical Sciences & Peking Union Medical College, and the National Center for Sexually Transmitted Disease Control (NCSTD) at Nanjing (approval number 2014-LS-026) for the use of anonymized samples and data collected during routine outpatient services to patients attending local dermatology and/or STD clinics.

Study population {#sec010}
----------------

The current study was a retrospective study based on clinical isolates and data of patients with confirmed *N*. *gonorrhoea* in the China-GRSP. The China-GRSP was launched by the NCSTD as a collaboration project consisting of a few clinics in 1987. China joined the WHO Western Pacific Gonococcal Antimicrobial Susceptibility Programme (GASP) in 1992 and then expanded China-GRSP to more participating clinics in 9 provinces (Guangdong, Guangxi, Hainan, Zhejiang, Sichuan, Tianjin, Xinjiang, Shanghai, and Chongqing) in 2007. In 2013, China-GRSP started collecting data on azithromycin resistance. At each participating clinic, routine medical consultation was provided to patients. Cultures for *N*. *gonorrhoeae* were performed in patients with a positive risk assessment. Data from patients with confirmed *N*. *gonorrhoeae* from 1 January 2013 to 31 December 2016 were used in this study. The study focused on 7 provinces ([Fig 1](#pmed.1002499.g001){ref-type="fig"}); Shanghai and Chongqing were not included in this study because these provinces did not collect data about azithromycin resistance. Selected demographic, behavioral, and clinical characteristics of the participants were extracted from outpatient medical records, i.e., from background information collected during the clinic visits.

![Geographic locations of the provinces where *N*. *gonorrhoeae* isolates were collected from patients.\
The number of isolates from each province is given in parentheses.](pmed.1002499.g001){#pmed.1002499.g001}

Isolation of *N*. *gonorrhoeae* {#sec011}
-------------------------------

As a patient could be infected at different anatomical sites (cervix/vagina, pharynx, rectum, and urethra), samples from more than 1 site were collected, if indicated. Rectal and pharyngeal samples were generally not obtained from heterosexual males. Samples were inoculated into selective Thayer-Martin (TM) medium and cultured in an incubator at 36°C in 5%--10% CO~2~ for 24 to 48 hours. With the cultured isolate samples, probable *N*. *gonorrhoeae* was identified based on colonial morphology (growth of typical appearing colonies), Gram stain (Gram-negative), and oxidase reaction (oxidase-positive intracellular diplococci in stained smears). Sugar fermentation tests were further performed if the identification was ambiguous. The gonococcal isolates were further sub-cultured from the selective TM medium to a nonselective medium, and the confirmed colonies were suspended in skim milk and frozen to −70°C until shipped to provincial central STD laboratories for antimicrobial susceptibility testing.

Antimicrobial susceptibility testing {#sec012}
------------------------------------

Agar dilution antimicrobial susceptibility tests were conducted at the central STD laboratories of the participating provinces according to WHO recommendations \[[@pmed.1002499.ref013]\]. Specifically, the isolates were cultured from frozen stocks onto selective TM medium and sub-cultured on GC medium base agar supplemented with hemoglobin powder and IsoVitaleX Enrichment (BD Diagnostics, Oxford, England) at 36°C with 5% to 10% CO~2~ for 18 to 20 hours at the central STD laboratories. The colonies were scraped, and suspensions of 10^7^ organisms per milliliter were prepared. Using a multipoint inoculator (10^4^ per point), the suspension was applied to antibiotic-containing medium (GC agar base supplemented with 10% defibrinated sheep blood; Nanjing Bianzhen Biotechnology, Nanjing, China) on a 9-cm diameter plate \[[@pmed.1002499.ref014]\]. The plate was cultured at 36°C with 5% to 10% CO~2~ for 18 to 24 hours, and the growth of gonococci in different concentrations of antibiotic (0.03, 0.06, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 mg/l for azithromycin and 0.008, 0.015, 0.03, 0.06, 0.125, 0.25, 0.5, and 1.0 mg/l for ceftriaxone) was observed and recorded. The minimum inhibitory concentration (MIC) was defined as the lowest concentration of an antibiotic that inhibited the growth of gonococci. MIC interpretive criteria were in accordance with the Clinical and Laboratory Standards Institute to define resistance or decreased susceptibility \[[@pmed.1002499.ref013],[@pmed.1002499.ref015]\]. For azithromycin, we categorized MIC values as susceptible (MIC ≤ 0.5 mg/l) or resistant (MIC ≥ 1.0 mg/l). For ceftriaxone, we categorized MICs as susceptible (MIC ≤ 0.06 mg/l) or decreased susceptibility (MIC ≥ 0.125 mg/l). For quality assurance, all the central STD laboratories participated in the external quality assurance program of the WHO Western Pacific GASP through the National STD Reference Laboratory in Nanjing.

Statistical analyses {#sec013}
--------------------

The development of the statistical analysis plan, including changes inspired by peer review, is described in [S1 Text](#pmed.1002499.s002){ref-type="supplementary-material"}. Those patients whose isolates were successfully cultured and for which MICs for azithromycin and/or ceftriaxone were determined were included in the final analyses. In this study, we calculated the prevalence rates and their 95% confidence intervals (CIs) of *N*. *gonorrhoeae* resistance to azithromycin (RTA), decreased susceptibility to ceftriaxone (DSC), and both RTA and DSC (RTA/DSC). Age was described as median and 25%--75% interquartile range (IQR) because the age data followed a left-skewed distribution. MIC was described as geometric mean and 95% CI because MICs were multiple values determined by serial dilutions. For MICs determined as above or below a specific value, we used the midpoint value between this specific value and the value of the next higher or lower dilution for calculating the geometric means. Bivariate analyses were conducted by chi-squared test or chi-squared test for trend. Multinomial logistic regression analysis was conducted to explore the associations of variables with being infected with strains of *N*. *gonorrhoeae* with RTA, DSC, or RTA/DSC. Variables with a significance level of *P* \< 0.10 in bivariate analyses were included in a multinomial logistic regression model. Adjusted odds ratios (AORs) and 95% CIs were estimated by adjusting for potential confounding factors that were included in the model. *P* ≤ 0.05 was set as the level of significance. Statistical analysis was done using SPSS for Windows (version 16.0; SPSS, Chicago, Illinois) and MedCalc for Windows (version 16.8; MedCalc Software, Mariakerke, Belgium).

The current study is reported as per Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([S1 Checklist](#pmed.1002499.s001){ref-type="supplementary-material"}).

Results {#sec014}
=======

Baseline characteristics of patients {#sec015}
------------------------------------

A total of 3,849 *N*. *gonorrhoeae* isolates were collected from 3,849 patients (males, 91.1%; females, 8.9%). Data on repeat infections in individuals were not available due to anonymization of the dataset during the study years. Of the 3,503 males who provided information on sexual orientation (99.9% of the male total), 3,451 (98.5%) were heterosexual and 52 (1.5%) were homosexual or bisexual. The median age was 31 years (IQR 26--40 years) for males and 31 years (IQR 25--43 years) for females. The majority (92.8%) of the participants were of Han ethnicity, and 50.2% were from the provinces along the coast, where more cases of gonorrhea were reported than in other areas \[[@pmed.1002499.ref016]\]. Previous infection with gonorrhea was reported in 15.0% of patients. Among the heterosexual patients, the majority of the isolates were from the urethra (99.4%) in males and the cervix or urethra (96.2%) in females. No patients were found to have a positive *N*. *gonorrhoeae* isolate at more than 1 anatomical site.

Azithromycin susceptibility {#sec016}
---------------------------

Out of 3,849 *N*. *gonorrhoeae* isolates, 3,827 (99.4%) and 3,849 (100.0%) had MIC results for azithromycin and ceftriaxone, respectively. The geometric mean azithromycin MIC was 0.32 mg/l (95% CI 0.31--0.34 mg/l), with a range of ≤0.05 to ≥8 mg/l. The prevalence of RTA (defined as MIC ≥ 1.0 mg/l) was 18.6% (710/3,827; 95% CI 17.4%--19.8%). The proportions of the isolates with different MICs of azithromycin by year are shown in [Fig 2](#pmed.1002499.g002){ref-type="fig"}. Neither the mean MIC nor the percentage of resistant strains appeared to change during the 2013--2016 study period, remaining between 0.31 mg/l and 0.34 mg/l and between 17.1% and 20.8%, respectively. Multinomial regression analysis ([Table 1](#pmed.1002499.t001){ref-type="table"}) indicates that RTA was significantly associated with younger age (AOR 0.99; 95% CI 0.98--1.00; *P* = 0.043) and being female (AOR 1.50; 95% CI 1.13--2.00; *P* = 0.005, compared with males).

![Proportion of *N*. *gonorrhoeae* isolates with different minimum inhibitory concentrations (mg/l) for azithromycin, by year.](pmed.1002499.g002){#pmed.1002499.g002}

10.1371/journal.pmed.1002499.t001

###### Associations between resistance to azithromycin or decreased susceptibility to ceftriaxone and demographic and clinical characteristics (multinomial regression analysis[\*](#t001fn001){ref-type="table-fn"}).

![](pmed.1002499.t001){#pmed.1002499.t001g}

  Characteristics                 Resistance to azithromycin (MIC ≥ 1.0 mg/l)[\*\*](#t001fn002){ref-type="table-fn"}   Decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/l)   Resistance to azithromycin and decreased susceptibility to ceftriaxone                                        
  ------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------------ ------------------- ---------------- -------------------
  Age group (years)               ――                                                                                   0.99 (0.98--1.00)[\*](#t001fn001){ref-type="table-fn"}       ――                                                                       1.00 (0.98--1.01)   ――               0.99 (0.97--1.01)
  Sex                                                                                                                                                                                                                                                                                             
      Male                        17.9 (624/3,486)                                                                     Reference                                                    11.1 (389/3,507)                                                         Reference           2.2 (77/3,486)   Reference
      Female                      25.2 (86/341)                                                                        1.50 (1.13--2.00)                                            8.2 (28/342)                                                             0.77 (0.47--1.27)   2.9 (10/341)     1.42 (0.71--2.84)
  Sexual orientation                                                                                                                                                                                                                                                                              
      Heterosexual                18.6 (699/3,763)                                                                     Reference                                                    10.9 (412/3,784)                                                         Reference           2.3 (86/3,677)   Reference
      Homosexual or bisexual      15.4 (8/52)                                                                          0.77 (0.34--1.74)                                            7.7 (4/52)                                                               0.45 (0.14--1.48)   1.9 (1/52)       1.08 (0.14--8.12)
  Previous gonococcal infection                                                                                                                                                                                                                                                                   
      Yes                         21.2 (122/576)                                                                       1.12 (0.87--1.43)                                            7.1 (41/577)                                                             0.68 (0.45--1.03)   2.3 (13/576)     0.78 (0.41--1.46)
      No                          18.1 (587/3,243)                                                                     Reference                                                    11.5 (374/3,264)                                                         Reference           2.3 (73/3,243)   Reference
  Residence along the coast                                                                                                                                                                                                                                                                       
      Yes                         17.1 (331/1,934)                                                                     1.00 (0.83--1.20)                                            12.9 (249/1,934)                                                         1.84 (1.44--2.36)   1.7 (32/1,902)   0.56 (0.35--0.88)
      No                          20.0 (379/1,893)                                                                     Reference                                                    8.8 (168/1,915)                                                          Reference           2.9 (55/1,838)   Reference

\*Reference value in the multinomial regression analysis: neither resistance to azithromycin nor decreased susceptibility to ceftriaxone.

\*\*22 results for azithromycin MIC are missing.

AOR, adjusted odds ratio; CI, confidence interval; MIC, minimum inhibitory concentration.

Ceftriaxone susceptibility {#sec017}
--------------------------

The geometric mean ceftriaxone MIC was 0.025 mg/l (95% CI 0.024--0.026 mg/l), with a range of ≤0.008 to ≥1.0 mg/l. The prevalence of DSC (defined as MIC ≥ 0.125 mg/l) was 10.8% (417/3,849; 95% CI 9.9%--11.9%). The proportions of isolates with different MICs for ceftriaxone are shown by year in [Fig 3](#pmed.1002499.g003){ref-type="fig"}. The percentage with DSC fluctuated between 9.7% and 12.2% over the period from 2013 to 2016. In the multinomial analysis ([Table 1](#pmed.1002499.t001){ref-type="table"}), DSC was significantly associated with residence in areas along the coast (AOR 1.84; 95% CI 1.44--2.36; *P* \< 0.001, compared with residence in other areas).

![Proportion of *N*. *gonorrhoeae* isolates with different minimum inhibitory concentrations (mg/l) for ceftriaxone, by year.](pmed.1002499.g003){#pmed.1002499.g003}

Resistance to azithromycin and decreased susceptibility to ceftriaxone {#sec018}
----------------------------------------------------------------------

The proportion of isolates resistant to azithromycin in those with DSC (21.0%, 87/415; 95% CI 17.3%--25.1%) was not statistically different from the proportion of isolates resistant to azithromycin in those susceptible to ceftriaxone (18.3%, 623/3,412; 95% CI 17.0%--19.6%) (chi-squared = 1.79; *P* = 0.18; [Table 2](#pmed.1002499.t002){ref-type="table"}). The prevalence of isolates with RTA/DSC was 2.3% (87/3,827; 95% CI 1.9%--2.8%). The prevalence increased from 1.9% (18/928; 95% CI 1.2%--3.0%) in 2013 to 3.3% (32/981; 95% CI 2.3%--4.6%) in 2016 (chi-squared for trend = 4.78; *P* = 0.03) ([Fig 4](#pmed.1002499.g004){ref-type="fig"}). Multinomial regression analysis ([Table 1](#pmed.1002499.t001){ref-type="table"}) indicates that residents in areas along the coast are less likely to be infected with strains with RTA/DSC (AOR 0.56; 95% CI 0.35--0.88; *P* = 0.013).

![Proportion of *N*. *gonorrhoeae* isolates with resistance to azithromycin (MIC ≥ 1.0 mg/l) and decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/l) from 2013 to 2016.\
MIC, minimum inhibitory concentration.](pmed.1002499.g004){#pmed.1002499.g004}

10.1371/journal.pmed.1002499.t002

###### Number and percentage of isolates susceptible or resistant to azithromycin by susceptibility breakpoints of ceftriaxone.

![](pmed.1002499.t002){#pmed.1002499.t002g}

  Ceftriaxone                                   Azithromycin[\*](#t002fn001){ref-type="table-fn"}                   
  --------------------------------------------- --------------------------------------------------- --------------- ----------------
  Susceptible (MIC ≤ 0.06 mg/l)                 623 (18.3%)                                         2,789 (81.7%)   3,412 (100.0%)
  Decreased susceptibility (MIC ≥ 0.125 mg/l)   87 (21.0%)                                          328 (79.0%)     415 (100.0%)
  Total                                         710 (18.6%)                                         3,117 (81.4%)   3,827 (100.0%)

\*There were 22 isolates without MIC data for azithromycin.

MIC, minimum inhibitory concentration.

Discussion {#sec019}
==========

The current study represents, to our knowledge, the first national surveillance on trends of susceptibility of *N*. *gonorrhoeae* to azithromycin and ceftriaxone over time in China. In addition, associations between susceptibility data and demographic and clinical characteristics of study participants were examined. Our findings indicate that the rate of dual RTA and DSC increased between 2013 and 2016. The prevalences of *N*. *gonorrhoeae* RTA and DSC found in this study in China were higher than those reported in many countries, including in Europe and the Americas \[[@pmed.1002499.ref017]--[@pmed.1002499.ref027]\] ([Table 3](#pmed.1002499.t003){ref-type="table"}). A high prevalence of RTA or DSC has also been reported in Japan, although the sample size of the available study was relatively small (less than 700 isolates in total over 3 years) \[[@pmed.1002499.ref027]\]. It is unclear whether circulating gonococcal strains with altered susceptibility to the key antibiotic agents in China acquired these mutations through domestic selective pressure or whether the strains have been imported. Antimicrobial resistant gonorrhea was documented first in Asia \[[@pmed.1002499.ref028],[@pmed.1002499.ref029]\], then emerged in other areas in the world. Although azithromycin monotherapy is not recommended for gonorrhea treatment in China, this antibiotic is widely used for treatment of chlamydial infection according to the national STD treatment guidelines \[[@pmed.1002499.ref030]\]. The prevalence of chlamydial infection is much higher than that of gonorrhea both among high-risk groups, such as female sex workers \[[@pmed.1002499.ref031],[@pmed.1002499.ref032]\] and men who have sex with men \[[@pmed.1002499.ref033]\], and in the general population \[[@pmed.1002499.ref034]\] in China. Overuse of macrolides for chlamydia and other infections could facilitate emergence of resistance in *N*. *gonorrhoeae* \[[@pmed.1002499.ref035]\]. Studies in China have reported that a high percentage (\>50%) of outpatient visits result in prescription of antibiotics \[[@pmed.1002499.ref036],[@pmed.1002499.ref037]\].

10.1371/journal.pmed.1002499.t003

###### Prevalence of resistance to azithromycin or decreased susceptibility to ceftriaxone among *N*. *gonorrhoeae* isolates collected from 2013 to 2016 in different countries.

![](pmed.1002499.t003){#pmed.1002499.t003g}

  Country/region by year                      Resistance to azithromycin (MIC ≥ 1.0 mg/l)   Decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/l)           
  ------------------------------------------- --------------------------------------------- ------------------------------------------------------------ ------- ---------------------------------------------
  United States                                                                                                                                                  
      2013 \[[@pmed.1002499.ref017]\]         5,945                                         3.6                                                          5,945   0.1
      2014 \[[@pmed.1002499.ref017]\]         5,093                                         7.1                                                          5,093   0.1
  Canada                                                                                                                                                         
      2014 \[[@pmed.1002499.ref018]\]                                                                                                                    3,809   0.05
  European Union                                                                                                                                                 
      2013 \[[@pmed.1002499.ref019]\]         1,994                                         5.4                                                          1,932   0.4[\*](#t003fn001){ref-type="table-fn"}
      2014 \[[@pmed.1002499.ref020]\]         2,147                                         7.9                                                          2,015   0.25[\*](#t003fn001){ref-type="table-fn"}
  United Kingdom                                                                                                                                                 
      2013 \[[@pmed.1002499.ref021]\]         1,750                                         1.6                                                          1,750   0.2
      2014 \[[@pmed.1002499.ref021]\]         1,568                                         1.0                                                          1,568   0.0
      2015 \[[@pmed.1002499.ref021]\]         1,699                                         9.8                                                          1,699   0.0
  Germany                                                                                                                                                        
      2010--2015 \[[@pmed.1002499.ref022]\]   266                                           7.1                                                                  
  Australia                                                                                                                                                      
      2013 \[[@pmed.1002499.ref023]\]         4,897                                         2.1                                                          4,897   0.6
      2014 \[[@pmed.1002499.ref024]\]         4,804                                         2.5                                                          4,804   0.6
      2015 \[[@pmed.1002499.ref025]\]         5,411                                         2.6                                                          5,411   0.1
  Zimbabwe                                                                                                                                                       
      2015--2016 \[[@pmed.1002499.ref026]\]                                                                                                              388     0.0
  Japan                                                                                                                                                          
      2013 \[[@pmed.1002499.ref027]\]         241                                           22.4[\*\*](#t003fn002){ref-type="table-fn"}                  241     31.5[\*\*](#t003fn002){ref-type="table-fn"}
      2014 \[[@pmed.1002499.ref027]\]         192                                           14.1[\*\*](#t003fn002){ref-type="table-fn"}                  192     32.8[\*\*](#t003fn002){ref-type="table-fn"}
      2015 \[[@pmed.1002499.ref027]\]         238                                           18.8[\*\*](#t003fn002){ref-type="table-fn"}                  238     29.4[\*\*](#t003fn002){ref-type="table-fn"}
  Our study in China                                                                                                                                             
      2013--2016                              3,827                                         18.6                                                         3,849   10.8

\*MIC \> 0.125 mg/l for ceftriaxone was used in this study.

\*\*These rate data came from personal communication with the corresponding author (Prof. Mitsuru Yasuda, Department of Urology, Gifu University Hospital) of the cited study.

MIC, minimum inhibitory concentration.

WHO and many countries have recommended dual antimicrobial therapy with ceftriaxone plus azithromycin for people with symptomatic and asymptomatic gonorrhea \[[@pmed.1002499.ref009]--[@pmed.1002499.ref011]\]. However, despite the high prevalence of DSC (more than 10%) in the current study, treatment failure of ceftriaxone has not been documented in China. It is important that clinicians be on high alert to recognize gonorrhea treatment failures so that they can be reported promptly to public health officials. The high and increasing prevalence of RTA/DSC found in the current study suggests the need for further consideration and validation of an appropriate regimen for treatment of gonorrhea in China.

Socioeconomic, behavioral, and clinical factors associated with antimicrobial resistance have been investigated by previous studies in China and other countries \[[@pmed.1002499.ref038]--[@pmed.1002499.ref040]\]. Interestingly, the factors independently associated with RTA and DSC were not the same in our study. Female patients had a higher risk of infection with an azithromycin-resistant strain than males. This finding was consistent with that reported in Amsterdam \[[@pmed.1002499.ref041]\] but different from that reported in Shanghai, where male sex was a significant predictor of tetracycline resistance \[[@pmed.1002499.ref038]\]. Our finding of an association of younger age with RTA is different from that reported in Shanghai, where probable resistance to ceftriaxone was most common among those in older age groups \[[@pmed.1002499.ref038]\]. In addition, in our study, DSC was more likely to occur in areas along the coast, but RTA/DSC was more prevalent in other areas. These associations may be related to transmission dynamics linked to the sexual networks of different populations or in different areas. In addition, the resistance patterns are also dependent on the population seeking care in the sentinel clinics. Further studies on genomic epidemiology and sexual networks among people infected with resistant strains are needed. In contrast to the expected association between previous gonorrhea infection---linked to potential exposure to the antibiotics---and antimicrobial resistance, our study indicated that previous infection with gonorrhea was not associated with risk of RTA or DSC.

There are some potential limitations to this study. First, although the current study was a national surveillance survey with a large number of isolates collected from 7 provinces in China, the sample accounts for roughly only 1% of reported cases of gonorrhea during the study period in the country. Geographically, less than a quarter of the 31 provinces in the country participated in the study, and most of them were located in the economically developed areas along the coast. Moreover, the majority of male participants provided urethral specimens (99.4% of men), and the majority of female participants provided cervical or urethral specimens (96.2% of women). Our sample overrepresents men because men are usually symptomatic and easy to identify for specimen collection. Another concern is that most pharyngeal and anal gonorrhea is asymptomatic, and repeat infections or repeat visits of anonymized patients to clinics during the study period may result in the true number of individuals sampled being smaller than the number of "patients" described here, although this difference is likely to be relatively small. In addition, only a small proportion of the study participants were homosexual or bisexual, and therefore the majority of men did not report any anal or pharyngeal sexual intercourse \[[@pmed.1002499.ref042]\]. All of these potential biases may limit the generalizability of the current study to all people infected with gonorrhea in China. Second, those isolates with MIC \> 0.5 mg/l for azithromycin or MIC \> 0.125 mg/l for ceftriaxone were not further categorized for susceptibility analysis to identify high-level RTA and/or resistance to ceftriaxone. Third, although molecular typing of *N*. *gonorrhoeae* was carried out in a few areas and reported previously \[[@pmed.1002499.ref043]\], it was not performed in the present survey. Future studies should include molecular and genomic analyses to investigate gonorrhea transmission and to track the spread of antimicrobial resistance \[[@pmed.1002499.ref044]\]. With regard to the treatment of gonorrhea in China, the national STD guidelines have not yet been updated to include dual therapy with ceftriaxone plus azithromycin for gonorrhea but recommend the use of azithromycin for treating potential infection with chlamydia among patients infected with gonorrhea. Further studies are needed to look into appropriate doses of ceftriaxone and azithromycin as well as use of other antibiotics in China.

In conclusion, the current study was a national study on the susceptibility of *N*. *gonorrhoeae* to azithromycin and ceftriaxone with implications for antibiotic choice for treatment of gonorrhea in China. An increasing trend of isolates with simultaneous RTA and DSC will likely impede the introduction of the currently WHO-recommended dual therapy in China. Therefore, evaluation of the efficacy of the dual therapy and the development of novel treatment strategies are urgently warranted in China. In addition, future resources should be dedicated to enhancing antimicrobial resistance surveillance by increasing both the number of laboratories performing susceptibility testing and the quality of susceptibility tests. The development of rapid diagnostics to promptly detect gonococcal infections and identify antimicrobial resistance is also urgently needed.
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